Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.

被引：0

作者：

Pond, Gregory Russell

Sonpavde, Guru

Choueiri, Toni K.

Qu, Angela Q.

Vaughn, David J.

Fougeray, Ronan

Niegisch, Guenter

Albers, Peter

Wong, Yu-Ning

Ko, Yoo-Joung

Sridhar, Srikala S.

Galsky, Matt D.

Petrylak, Daniel Peter

Beer, Tomasz M.

Stadler, Walter Michael

O'Donnell, Peter H.

Sternberg, Cora N.

Rosenberg, Jonathan E.

Molins, Joaquim Bellmunt

机构：

[1] McMaster Univ, Hamilton, ON, Canada

[2] Texas Oncol, Houston, TX USA

[3] Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA

[4] Harvard Univ, Brigham & Womens Hosp, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst,Med Sch, Boston, MA 02115 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[7] Inst Rech Pierre Fabre, Boulogne, France

[8] Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany

[9] Univ Dusseldorf, D-40225 Dusseldorf, Germany

[10] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[11] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[12] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada

[13] Mt Sinai Sch Med, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY USA

[14] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA

[15] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[16] Univ Chicago, Chicago, IL 60637 USA

[17] San Camillo Hosp, Rome, Italy

[18] Forlanini Hosp, Rome, Italy

[19] Univ Hosp del Mar IMIM, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4522

引用

页数：1

共 50 条

[1] PROGNOSTIC STRATIFICATION OF ADVANCED UROTHELIAL CARCINOMA (UC) RECEIVING SECOND-LINE SYSTEMIC THERAPY INCLUDING TIME FROM PRIOR CHEMOTHERAPY (TFPC) AS A PROGNOSTIC FACTOR
Sonpavde, G.
Pond, G. R.
Choueiri, T. K.
Fougeray, R.
Niegisch, G.
Wong, Y.
Sridhar, S. S.
Stadler, W. M.
Sternberg, C. N.
Bellmunt, J.
ANNALS OF ONCOLOGY, 2012, 23 : 265 - 266
[2] Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design
Pond, Gregory R.
Bellmunt, Joaquim
Fougeray, Ronan
Choueiri, Toni K.
Qu, Angela Q.
Niegisch, Guenter
Albers, Peter
Di Lorenzo, Giuseppe
Salhi, Yacine
Galsky, Matthew D.
Agarwal, Neeraj
Necchi, Andrea
Sonpavde, Guru
CLINICAL GENITOURINARY CANCER, 2013, 11 (04) : 495 - 500
[3] Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.
Sonpavde, Guru
Bellmunt, Joaquim
Rosenberg, Jonathan E.
Bajorin, Dean F.
Regazzi, Ashley Marie
Choueiri, Toni K.
Qu, Angela Q.
Niegisch, Guenter
Albers, Peter
Necchi, Andrea
di Lorenzo, Giuseppe
Fougeray, Ronan
Wong, Yu-Ning
Sridhar, Srikala S.
Ko, Yoo-Joung
Milowsky, Matthew I.
Galsky, Matt D.
Pond, Gregory Russell
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[4] Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC)
Sonpavde, Guru
Pond, Gregory Russell
Agarwal, Neeraj
Choueiri, Toni K.
Qu, Angela Q.
Fougeray, Ronan
Salhi, Yacine
Vaughn, David J.
James, Nicholas David
Niegisch, Guenter
Albers, Peter
Galsky, Matt D.
Wong, Yu-Ning
Stadler, Walter Michael
O'Donnell, Peter H.
Vogelzang, Nicholas J.
Sridhar, Srikala S.
Ko, Yoo-Joung
Sternberg, Cora N.
Bellmunt, Joaquim
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[5] Gemcitabine and ifosfamide (GI) as a second-line systemic chemotherapy for cisplatin-failed advanced urothelial carcinoma (UC).
Pu, YS
Lin, CC
Hsu, CH
Keng, HY
Huang, CY
Chen, J
Cheng, AL
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 441S - 441S
[6] Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.
Pond, Gregory Russell
Bellmunt, Joaquim
Fougeray, Ronan
Choueiri, Toni K.
Qu, Angela Q.
Salhi, Yacine
Niegisch, Guenter
Albers, Peter
Di Lorenzo, Giuseppe
Galsky, Matt D.
Necchi, Andrea
Sonpavde, Guru
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] THE MODIFIED GLASGOW PROGNOSTIC SCORE IS A POWERFUL PROGNOSTIC FACTOR IN METASTATIC UROTHELIAL CARCINOMA PATIENTS RECEIVING SECOND-LINE CHEMOTHERAPY
Matsumoto, Ryuji
Abe, Takashige
Ishizaki, Junji
Minami, Keita
Harabayashi, Toru
Sazawa, Ataru
Mochizuki, Tango
Akino, Tomoshige
Murakumo, Masashi
Miyajima, Naoto
Tsuchiya, Kunihiko
Kikuchi, Hiroshi
Miyata, Haruka
Osawa, Takahiro
Maruyama, Satoru
Murai, Sachiyo
Shinohara, Nobuo
JOURNAL OF UROLOGY, 2018, 199 (04): : E1045 - E1045
[8] Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC)
Sonpavde, Guru
Pond, Gregory Russell
di Lorenzo, Giuseppe
Buonerba, Carlo
Rozzi, Antonio
Lanzetta, Gaetano
Necchi, Andrea
Giannatempo, Patrizia
Raggi, Daniele
Matsumoto, Kazurrosa
Choueiri, Toni K.
Mullane, Stephanie A.
Niegisch, Guenter
Albers, Peter
Lee, Jae-Lyun
Kitamura, Hiroshi
Kume, Haruki
Bellmunt, Joaquim
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[9] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J.
de Wit, R.
Vaughn, D. J.
Fradet, Y.
Lee, J. -L.
Fong, L.
Vogelzang, N. J.
Climent, M. A.
Petrylak, D. P.
Choueiri, T. K.
Necchi, A.
Gerritsen, W.
Gurney, H.
Quinn, D. I.
Culine, S.
Sternberg, C. N.
Mai, Y.
Poehlein, C. H.
Perini, R. F.
Bajorin, D. F.
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1015 - 1026
[10] Pembrolizumab as second-line therapy for advanced urothelial carcinoma
Douchet, G.
ONCOLOGIE, 2017, 19 (5-6) : 205 - 206

← 1 2 3 4 5 →